We are live on ! Find out more
ACOR

Acorda Therapeutics

Delisted

ACOR was delisted on the 11th of April, 2024.

190 hedge funds and large institutions have $1.53B invested in Acorda Therapeutics in 2015 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 82 increasing their positions, 53 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

55% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 53

31% more call options, than puts

Call options by funds: $7.54M | Put options by funds: $5.77M

6% more funds holding

Funds holding: 179190 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

15% less capital invested

Capital invested by funds: $1.81B → $1.53B (-$281M)

Holders
190
Holders Change
+11
Holders Change %
+6.15%
% of All Funds
5.06%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
31
Increased
82
Reduced
53
Closed
18
Calls
$7.54M
Puts
$5.77M
Net Calls
+$1.77M
Net Calls Change
-$6.11M

ACOR Hedge Fund Activity: Q1 2015 in Review

190 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2015, worth a combined $1.53B — down 15% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ACOR positions and 18 closed out — a net gain of 13 holders — while 82 added to existing stakes and 53 trimmed.

The largest buyer was Millennium Management, adding an estimated $25.9M. The largest seller was Visium Asset Management, cutting an estimated $35.4M.

  • 190 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2015, up from 179 in Q4 2014.
  • Funds reported $1.53B of Acorda Therapeutics stock for Q1 2015, down 15% quarter-over-quarter.
  • 31 funds opened new Acorda Therapeutics positions in Q1 2015 and 18 closed out, a net change of +13 holders.
  • The largest Acorda Therapeutics buyer in Q1 2015 was Millennium Management, an estimated $25.9M added.
  • The largest Acorda Therapeutics seller in Q1 2015 was Visium Asset Management, an estimated $35.4M sold.

Based on aggregated 13F filings for Q1 2015.